Patients with metastatic breast cancer (MBC) with isolated CNS metastases represent a “distinct population,” according to the researchers of a study published in Therapeutic Advances in Medical Oncology.

In this retrospective analysis, researchers assessed 22,266 patients from the French Epidemiological Strategy and Medical Economics (ESME) MBC database who underwent treat for MBC between 2008 and 2016. The outcomes of interest were progression-free survival (PFS) and overall survival (OS), which were estimated using the Kaplan-Meier method.

Out of the total population, just over 4% patients had isolated first-site CNS metastases or combined with extra-CNS metastases, with longer OS observed in the group with isolated CNS metastases (16.9 versus 13.9 months, adjusted HR = 1.69 (95% CI: 1.50-1.91), p < 0.001). Among people with CNS metastases, older age, TN subtype, MBC-free interval of 6-12 months, lower performance status, and WBRT were associated with poorer survival.

“Patients with isolated CNS metastases at MBC diagnosis represent a distinct population for which the role of systemic therapy needs to be further investigated in prospective studies,” the researchers concluded.



Keywords: CNS metastases, breast cancer, real-world data